Lamellar Biomedical
BioTech/Drugs - North Lanarkshire, SCO, UK
Lamellar Biomedical Employees
Lamellar Biomedical Details
Lamellar Biomedical is an innovative biotechnology company developing our proprietary LAMELLASOME™ based therapies to transform the treatment of complex and rare lung disorders, either as biologically active products in their own right or by delivering active payloads. Along with our in-house research and development team, we are collaborating with world-renowned institutions and universities to develop therapeutics that capitalise on the unique properties of LAMELLASOME™ formulations that protect lung tissues.Lamellar's lead products are:IPF-Lamellasome: abates pulmonary fibrosis by reducing both myofibroblasts and collagen production. IPF-Lamellasome has the potential to become the first line therapy and the new standard of care in the treatment of Idiopathic Pulmonary Fibrosis (IPF) IPF.Muco-ease: increases the fluidity of thickened human mucus and may slow disease progression in mild and moderate Cystic Fibrosis (CF) by improving mucociliary clearanceLamellasome treatment for COVID-19 intended to prevent or mitigate progression of respiratory symptoms to pneumonitis and ARDS, promoting survival ad potentially protecting lungs from fibrotic sequelae of survivors These therapies are based on LAMELLASOME™ therapies' abilities to:Reduce inflammatory responses in pulmonary tissue.Interrupt the onset and progression of pulmonary inflammation, pneumonitis and the development of fibrosis.Modulate tissue surface tension, moisture retention and lubrication.
Lamellar Biomedical Technologies
Captcha
reCAPTCHA
Email Providers
Outlook
Tag Management
Google Tag Manager
Other
Mobile Friendly